Sign Up Today and Learn More About TwinStrand Biosciences Stock
Invest in or calculate the value of your shares in TwinStrand Biosciences or other pre-IPO companies through EquityZen's platform.
TwinStrand Biosciences Stock (TWBI)
TwinStrand Biosciences develops and commercializes the Duplex Sequencing™ technology for DNA sequencing.
About TwinStrand Biosciences Stock
Founded
2015
Headquarters
Seattle, WA, US
Industries
Science and Engineering, Health Care, Biotechnology
TwinStrand Biosciences Press Mentions
Stay in the know about the latest news on TwinStrand Biosciences
Exact Sciences secures exclusive license for cancer tech
investing • Aug 03, 2024
TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology
prnewswire • Aug 03, 2024
Eleonora Juarez, PhD on LinkedIn: #layoffs #opentowork #biotech
linkedin • Jun 26, 2024
June Hope on LinkedIn: TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex…
linkedin • May 24, 2024
TwinStrand Biosciences Initiates Regulatory Approval Process for Duplex Sequencing Mutagenesis Assays with OECD
prnewswire • May 24, 2024
TwinStrand Biosciences Management
Leadership team at TwinStrand Biosciences
Chief Legal Officer
Jeff Grainger
Co-Founder & Chief Scientific Officer
Jesse Salk
Join now and verify your accreditation status to gain access to:
- TwinStrand Biosciences Current Valuation
- TwinStrand Biosciences Stock Price
- TwinStrand Biosciences Management
- Available deals in TwinStrand Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- TwinStrand Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- TwinStrand Biosciences Revenue and Financials
- TwinStrand Biosciences Highlights
- TwinStrand Biosciences Business Model
- TwinStrand Biosciences Risk Factors
- TwinStrand Biosciences Research Report from SACRA Research
Trading TwinStrand Biosciences Stock
How to invest in TwinStrand Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like TwinStrand Biosciences through EquityZen funds. These investments are made available by existing TwinStrand Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell TwinStrand Biosciences stock?
Shareholders can sell their TwinStrand Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 45K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
